Physician profile
Lindsay Nicole Ogle
NPI 1346703923
$1,040.26
in general payments reported to CMS, 2019-2025
17 companies · $61.90 in 2025
The $61.90 reported for 2025 was less than what a typical Obesity Medicine (Family Medicine) provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $145 · 2023: $409 · 2024: $425 · 2025: $61.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $895.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $279.65 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $111.46 | 2023-2024 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $99.11 | 2022-2024 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $79.99 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $77.52 | 2023-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.36 | 2022-2024 | Jardiance |
| Amgen INC. | $64.62 | 2022-2023 | Repatha, Otezla |
| Pfizer INC. | $61.04 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $37.30 | 2024 | Xarelto |
| Sumitomo Pharma America, INC. | $30.02 | 2023-2024 | Gemtesa |
| Exact Sciences Corporation | $28.61 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $24.18 | 2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $20.76 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $16.13 | 2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Teva Pharmaceuticals USA, INC. | $15.18 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.83 | 2023 | Belsomra, Steglatro |
| Ibsa Pharma INC. | $13.50 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Ogle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.